Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban

Journal of Peptide Science

Volumn 11, Issue 10, 2005, Pages 593-608

  Manning, Maurice ^a   Cheng, Ling Ling ^a   Stoev, Stoytcho ^a   Ching Wo, Nga ^b   Chan, W Y ^b   Szeto, Hazel H ^b   Durroux, Thierry ^c   Mouillac, Bernard ^c   Barberis, Claude ^c  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c INSERM   (France)

Author keywords

Antagonists; Atosiban; Barusiban; Human OT receptor; Oxytocin; V1a receptor; Vasopressin

Indexed keywords

ATOSIBAN; BETA MERCAPTO BETA,BETA PENTAMETHYLENEPROPIONIC ACID(2 DEXTRO 2 NAPHTHYLALANINE 4 THREONINE 9 ETHYLENEDIAMINE 10,4 HYDROXYPHENYLACETYL)ORNITHINE VASOTOCIN; BETA MERCAPTO BETA,BETA PENTAMETHYLENEPROPIONIC ACID(2 DEXTRO 2 NAPHTHYLALANINE 4 THREONINE 9 ETHYLENEDIAMINE)ORNITHINE VASOTOCIN; BETA MERCAPTO BETA,BETA PENTAMETHYLENEPROPIONIC ACID(2 DEXTRO 2 NAPHTHYLALANINE 4 THREONINE 9 TYROSINAMIDE)ORNITHINE VASOTOCIN; BETA MERCAPTO BETA,BETA PENTAMETHYLENEPROPIONIC ACID(2 LEVO 2 NAPHTHYLALANINE 4 THREONINE 9 ETHYLENEDIAMINE 10,4 HYDROXYPHENYLACETYL)ORNITHINE VASOTOCIN; BETA MERCAPTO BETA,BETA PENTAMETHYLENEPROPIONIC ACID(2 LEVO 2 NAPHTHYLALANINE 4 THREONINE 9 ETHYLENEDIAMINE)ORNITHINE VASOTOCIN; BETA MERCAPTO BETA,BETA PENTAMETHYLENEPROPIONIC ACID(2 LEVO 2 NAPHTHYLALANINE 4 THREONINE 9 TYROSINAMIDE)ORNITHINE VASOTOCIN; DES 9 GLYCINAMIDE [1 (BETA MERCAPTO BETA,BETA PENTAMETHYLENEPROPIONIC ACID) 2 O METHYLTYROSINE 4 THREONINE]ORNITHINE VASOTOCIN; DESGLYCINAMIDE(BETA MERCAPTO BETA,BETA PENTAMETHYLENEPROPIONIC ACID)(2 DEXTRO 2 NAPHTHYLALANINE 4 THREONINE)ORNITHINE VASOTOCIN; DESGLYCINAMIDE(BETA MERCAPTO BETA,BETA PENTAMETHYLENEPROPIONIC ACID)(2 LEVO 2 NAPHTHYLALANINE 4 THREONINE)ORNITHINE VASOTOCIN; OXYTOCIN ANTAGONIST; OXYTOCIN RECEPTOR; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR;

ANIMAL CELL; ANTIDIURESIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; SOLID PHASE SYNTHESIS;

ANIMALS; BIOLOGICAL ASSAY; CHO CELLS; CRICETINAE; DRUG DESIGN; FEMALE; HORMONE ANTAGONISTS; HUMANS; OLIGOPEPTIDES; OXYTOCIN; RATS; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; VASOTOCIN;

EID: 27144511213     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.667     Document Type: Article

References (122)

1. Norwitz ER, Robinson JN, Challis JRG. The control of labor. N. Engl. J. Med. 1999; 341: 660-666.
2. Goodwin TM. The Gordian knot of developing tocolytics. J. Soc. Gynecol. Invest. 2004; 11: 339-341.
3. Strategies to prevent the morbidity and mortality associated with prematurity. Proceedings from the 1st International Preterm Labour Congress, June 2002, Montreux, Switzerland. Grant JM, Husslein P, Lamont R (eds). Br. J. Obstet. Gynaecol. 2003; 110 (Suppl 20).
4. Challis JRG, Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocr. Rev. 2000; 21: 514-550.
5. Schwarz MK, Page P. Preterm labour: An overview of current and emerging therapeutics. Curr. Med. Chem. 2003; 10: 1441-1468.
6. Ingemarsson I, Lamont RF. An update on the controversies of tocolytic therapy for the prevention of preterm birth. Acta Obstet. Gynecol. Scand. 2003; 82: 1-9.
7. Fuchs AR, Fuchs F, Husslein P, Soloff MS, Fernstrom MJ. Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor. Science 1982; 215: 1396-1398.
8. Anderson LF, Lyndrup J, Akerlund M, Melin P. Oxytocin receptor blockade: A new principle in the treatment of preterm labor? Am. J. Perinatol. 1989; 6: 196-199.
9. Chan WY, Chen DL. Myometrial oxytocin receptors and prostaglandin in the parturition process in the rat. Biol. Reprod. 1992; 46: 58-64.
10. Antonijevic IA, Douglas AJ, Dye S, Bicknell RJ, Leng G, Russell JA. Oxytocin antagonists delay the initiation of parturition and prolong its active phase in rats. J. Endocrinol. 1995; 145: 97-103.
11. Berankova Z, Rychlik I, Jost K, Rudinger J, Sorm F. Inhibition of the uterus-contracting effect of oxytocin by O-methyl oxytocin. Collect. Czech. Chem. Commun. 1961; 26: 2673-2675.
12. Schulz H, du Vigneaud V. Synthesis of 1-L-penicillamine-oxytocin, 1-D-penicillamine-oxytocin and 1-deaminopenicillamine-oxytocin, potent inhibitors of the oxytocic response of oxytocin. J. Med. Chem. 1966; 9: 647-650.
13. Bisset GV, Clark BJ, Krejci I, Polacek I, Rudinger J. Some pharmacological properties of a synthetic oxytocin analogue 1-N-carbamoyl-hemicystine-2-O-methyltyrosine (carbamoyl-methyloxytocin), an antagonist to the neurohypophysial hormones. Br. J. Pharmacol. 1970; 40: 342-360.
14. Vavrek RJ, Ferger MF, Allen GA, Rich DH, Blomquist AT, du Vigneaud V. Synthesis of three oxytocin analogs related to [1-deaminopenicillamine]-oxytocin possessing antioxytocic activity. J. Med. Chem. 1972; 15: 123-126.
15. Kaurov OA, Martynov VF, Mikhailov YuD, Auna ZP. Synthesis of new oxytocin analogs modified in the 2-position. Z. Obshchei Khimii 1972; 42: 1654.
16. Nestor JJ Jr, Ferger MF, du Vigneaud V. [1-β-mercapto-β,β-pentamethylenepropionic acid]oxytocin, a potent inhibitor of oxytocin. J. Med. Chem. 1975; 18: 284-287.
17. Manning M, Lowbridge J, Sawyer WH. The design of neurohypophysial peptides possessing selectively enhanced and inhibitory properties. In Peptides: Chemistry, Structure and Biology, Walter R, Meienhofer J (eds). Ann Arbor Science: Ann Arbor, 1975; 737-750.
18. Manning M, Lowbridge J, Seto J, Haldar J, Sawyer WH. [1-Deaminopenicillamine, 4-threonine]-oxytocin, a potent inhibitor of oxytocin. J. Med. Chem. 1978; 21: 179-182.
19. Lowbridge J, Manning M, Seto J, Haldar J, Sawyer WH. Synthetic antagonists of in vivo responses by the rat uterus to oxytocin. J. Med. Chem. 1979; 22: 565-569.
20. Manning M, Bankowski K, Kruszynski M, Seto J, Haldar J, Sawyer WH. Synthetic analogs of oxytocin which possess enhanced antioxytocic and antivasopressor potencies in vitro. In Peptides 1980, Brunfeldt K (ed.). Scriptor: Copenhagen, 1981; 534-540.
21. Sawyer WH, Haldar J, Gazis D, Seto J, Bankowski K, Lowbridge J, Turan A, Manning M. The design of effective in vivo antagonists of rat uterus and milk ejection responses to oxytocin. Endocrinology 1980; 106: 81-91.
22. Bankowski K, Manning M, Seto J, Haldar J, Sawyer WH. Design and synthesis of potent in vivo antagonists of oxytocin. Int. J. Pept. Protein Res. 1980; 16: 382-391.
23. Hruby VJ, Mosberg HI, Hadley M, Chan WY, Powell AM. Synthesis, pharmacological, conformational, and dynamic studies of the potent hormone antagonist [1-penicillamine, 4-threonine]oxytocin. Int. J. Pept. Protein Res. 1980; 16: 372-381.
24. Lebl M, Barth T, Servitova L, Slaninova J, Jost K. Oxytocin analogues with inhibitory properties, containing in position 2 a hydrophobic amino acid of D-configuration. Collect. Czech. Chem. Commun. 1985; 50: 132-145.
25. Chan WY, Hruby VJ, Rockway TW, Hlavacek J. Design of oxytocin antagonists with prolonged action: Potential tocolytic agents for the treatment of pre-term labor. J. Pharmacol. Exp. Ther. 1986; 239: 84-87.
26. Melin P, Trojnar J, Johansson B, Vilhardt H, Akerlund M. Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J. Endocrinol. 1986; 111: 125-131.
27. Chan WY, Rockway TW, Hruby VJ. Long-acting oxytocin antagonists: effects of 2-D-stereoisomerism substitution on antagonistic potency and duration of action. Proc. Soc. Exp. Biol. Med. 1987; 185: 187-192.
28. Rekowski P, Melin P, Lammek B. Synthesis and some pharmacological properties of 2 new antagonists of oxytocin. Pol. J. Pharmacol. Pharm. 1987; 39: 303-307.
29. 9]OVT: a selective oxytocin receptor ligand. Eur. J. Pharmacol. 1988; 147: 197-207.
30. Manning M, Kruszynski M, Bankowski K, Olma A, Lammek B, Cheng LL, Klis WA, Seto J, Haldar J, Sawyer WH. Solid phase synthesis of sixteen potent (selective and nonselective) in vivo antagonists of oxytocin. J. Med. Chem. 1989; 32: 382-391.
31. Lankiewicz L, Glanz D, Grzonka Z, Slaninova J, Barth T, Fahrenholz F. Synthesis and biological-activity of oxytocin analogs with beta-amino acids in position-2. B. Pol. Acad. Sci. Chem. 1989; 37: 45-51.
32. Wilson Jr L, Parsons MT, Ouano L, Flouret G. A new tocolytic agent: development of an oxytocin antagonist for inhibiting uterine contractions. Am. J. Obstet. Gynecol. 1990; 163: 195-202.
33. Flouret G, Brieher W, Majewski T, Mahan K, Wilson Jr L. Some pharmacological properties of cyclic and linear analogs obtained by substituting each residue of an oxytocin antagonist with D-tryptophan. Int. J. Pept. Protein Res. 1991; 38: 169-175.
34. Flouret G, Brieher W, Mahan K, Wilson Jr L. Design of potent oxytocin antagonists featuring D-tryptophan at position 2. J. Med. Chem. 1991; 34: 642-646.
35. Flouret G, Brieher W, Majewski T, Mahan K, Wilson Jr L. Improvement in potency of an oxytocin antagonist after systematic substitutions with L-tryptophan. J. Med. Chem. 1991; 34: 2089-2094.
36. Smith DD, Slaninova J, Hruby VJ. Structure-activity studies of a novel bicyclic oxytocin antagonist. J. Med. Chem. 1992; 35: 1558-1563.
37. Prohazka Z, Slaninova J, Barth T, Stierandova A, Trojnar J, Melin P, Lebl M. Analogs of deamino carba oxytocin with inhibitory properties - synthesis and biological-activities. Collect. Czech. Chem. Commun. 1992; 57: 1335-1344.
38. Pal BC, Slaninova J, Barth T, Trojnar J, Lebl M. Synthesis and properties of hormonogen and inhibitorogen type oxytocin analogs. Collect. Czech. Chem. Commun. 1992; 57: 1345-1351.
39. Lebl M, Toth G, Slaninova J, Hruby VJ. Conformationally biased analogs of oxytocin. Int. J. Pept. Protein Res. 1992; 40: 148-151.
40. 6-substituted analogue. J. Med. Chem. 1993: 36: 747-749.
41. Williams PD, Anderson PS, Ball RG, Bock MG, Carroll LA, Chiu S-HL, Clineschmidt BV, Culberson JC, Erb JM, Evans BE, Fitzpatrick SL, Freidinger RM, Kaufman MJ, Lundell GF, Murphy JS, Pawluczyk JM, Perlow DS, Pettibone DJ, Pitzenberg SM, Thompson KL, Veber DF. 1-(((7,7-Dimethyl-2(S)-2(S)-amino-4-(methylsuffonyl) butyramido)bicyclo[2.2.1]-heptan (S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperazine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing pre-term labor. J. Med. Chem. 1994; 37: 565-571.
42. Jezek R, Zertova M, Slaninova J, Majer P, Prohazka Z. Antagonistic analogs of oxytocin with substituted phenylalanine or tyrosine in position 2. Collect. Czech. Chem. Commun. 1994; 59: 1430-1438.
43. Mayer P, Slaninova J, Lebl M. Synthesis of methylated phenylalanines via hydrogenolysis of corresponding 1,2,3,4-tetrahydroisoquinoline-3-caboxylic acids. Synthesis and biological activity of oxytocin analogs with methylated phenylalanines in position 2. Int. J. Pept. Protein Res. 1994; 43: 62-68.
44. Pavo I, Slaninova J, Klein U, Fahrenzolz F. Enhanced selectivity of oxytocin antagonists containing sarcosine in position-7. J. Med. Chem. 1994: 37: 255-259.
45. Prohazka Z, Slaninova J. The 1- and 2-naphthylalanine analogs of oxytocin and vasopressin. Collect. Czech. Chem. Commun. 1995; 60: 2170-2177.
46. 6 interchange in selective and non-selective antagonists of vasopressin and oxytocin. J. Med. Chem. 1995; 38: 1762-1769.
47. Manning M, Miteva K, Pancheva S, Stoev S, Wo NC, Chan WY. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: Comparisons with atosiban. Int. J. Pept. Protein Res. 1995; 46: 244-252.
48. 1a receptor antagonists. New approaches for the design of potential tocolytics for preterm labor. J. Pharmacol. Exp. Ther. 1996; 277: 999-1003.
49. Williams PD, Clineschmidt BV, Erb JM, Freidinger RM, Guidotti MT, Lis EV, Pawluczyk JM, Pettibone DJ, Reiss DR, Veber DF, Woyden CJ. 1-(1-[4-[N-acetyl-4-piperidinyl]oxy]-2-methoxybenzoyl] piperidin-4-yl)-4H-3,1-benzoxazin-2(1H)-one (L371,257): a new, orally bioavailable, non-peptide oxytocin antagonist. J. Med. Chem. 1995; 38: 4634-4636.
50. Lian SB, Shenderovich MD, Zhang ZG, Maletinska L, Slaninova J, Hruby VJ. Substitution of the side-chain-constrained amino acids beta-methyl-2′, 6-dimethy-4′-methoxytyrosine in position 2 of a bicyclic oxytocin analogue provides unique insights into the bioactive topography of oxytocin antagonists. J. Am. Chem. Soc. 1998; 120: 7393-7394.
51. Wisniewski K, Trojnar J, Riviere P, Haigh R, Yea C, Ashworth D, Melin P, Nilsson A. The synthesis of new class of oxytocin antagonists. Bioorg. Med. Chem. Lett. 1999; 9: 2801-2804.
52. Prohazka Z, Zertova M, Slaninova J. The analogs of oxytocin and D-homoarginine vasopressin with bulky substituted phenylalanine in position 2. Lett. Pept. Sci. 2000; 7: 179-185.
53. Sobocinska M, Lempicka E, Konieczna E, Derdowska I, Lammek B, Melhem S, Kozik W, Janecka J, Janecki M, Trzectak HI. Analogues of arginine vasopressin modified in position 2 or 3 with naphthylalanine: selective antagonists of oxytocin in-vitro. J. Pharm. Pharmacol. 2000; 52: 1105-1112.
54. Manning M, Stoev S, Cheng LL, Wo NC, Chan WY. Design of oxytocin antagonists, which are more selective than atosiban. J. Pept. Sci. 2001; 7: 449-465.
55. Stoev S, Cheng LL, Manning M, Wo NC, Chan WY, Durroux T, Barberis C. Design of oxytocin antagonists which are more selective than atosiban in rat bioassays and in human receptor assays. In Peptides: The Wave of the Future, Lebl M, Houghten R (eds). American Peptide Society: San Diego, CA, 2001; 699-700.
56. 1a receptors. J. Med. Chem. 2002; 45: 2579-2588.
57. Flouret G, Majewski T, Balaspiri L, Brieher W, Mahan K, Chaloin O, Wilson L, Jr, Slaninova J. Antagonists of oxytocin featuring replacement with modified beta-mercaptopropionic acids at position 1. J. Pept. Sci. 2002; 8: 314-326.
58. Cirillo R, Gillio Tos E, Schwarz MK, Quattropani A, Scheer A, Missotten M, Dorbais J, Nichols A, Borrelli F, Giachetti C, Golzio L, Marinelli P, Thomas RJ, Chevillard C, Laurent F, Portet K, Barberis C, Chollet A. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4- (methoxyimino)-1-[(2′-methyl[1,1′-biphenyl]-4-yl) carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. J. Pharmacol. Exp. Ther. 2003; 306: 253-261.
59. Flouret G, Chaloin O, Slaninova J. Analogues of a potent oxytocin antagonist with truncated C-terminus or shorter amino acid side chain of the basic amino acid at position 8. J. Pept. Sci. 2003; 9: 393-401.
60. Nilsson L, Reinheimer T, Steinwall M, Akerlund M. FE 200 440: a selective oxytocin antagonist on the term-pregnant human uterus. Br. J. Obstet. Gynaecol. 2003; 110: 1025-1028.
61. t)] in positions 8 or 9. Peptides 2003; 24: 1425-1431.
62. Serradeil-Le Gal C, Valette G, Foulon L, Germain G, Advenier C, Naline E, Bardou M, Martinolle J-P, Pouzet B, Raufaste D, Garcia C, Double-Cazanave E, Pauly M, Pascal M, Barbier A, Scatton B, Maffrand J-P, Le Fur G. SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1- (2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro- 1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor. J. Pharmacol. Exp. Ther. 2004: 309: 414-424.
63. Hruby VJ, Smith CJ. Structure-activity relationships of neurohypophyseal peptides. In The Peptides, Udenfriend S, Meienhofer J (eds), vol. 8: Chemistry, Biology and Medicine of Neurohypophyseal Hormones and their Analogs, Smith CW (ed.). Academic Press: Orlando, FL, 1987; 177-207.
64. Lebl M. Analogs with inhibitory properties. In Handbook of Neurohypophyseal Hormone Analogs, Jost K, Lebl M, Brtnik F (eds), vol. II, Part 1. CRC Press: Boca Raton, FL, 1987; 17-74.
65. Manning M, Sawyer WH. Discovery, development and some uses of vasopressin and oxytocin antagonists. J. Lab. Clin. Med. 1989; 114: 617-632. [Published erratum appears in J. Lab. Clin. Med. 1990; 115: 530].
66. Manning M, Sawyer WH. Design, synthesis and some uses of receptor specific agonists and antagonists of vasopressin and oxytocin. J. Recept. Res. 1993; 13: 195-214.
67. Manning M, Cheng LL, Klis WA, Stoev S, Przybylski J, Bankowski K, Sawyer WH, Barberis C, Chan WY. Advances in the design of selective antagonists, potential tocolytics and radioiodinated ligands for oxytocin receptors. In Oxytocin: Cellular and Molecular Approaches in Medicine and Research, Ivell R, Russell J (eds). Plenum Press: New York, 1995; 559-583.
68. Manning M, Stoev S, Cheng LL, Wo NC, Chan WY. Novel potent and selective antagonists and radioiodinated ligands for oxytocin and vasopressin receptors. In Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research, Saito T, Kurokawa K, Yoshida S (eds). Elsevier: Amsterdam, 1995; 21-38.
69. Freidinger RM, Pettibone DJ. Small molecule ligands for oxytocin and vasopressin receptors. Med. Res. Rev. 1997; 17: 1-16.
70. Vatish M, Thornton S. Oxytocin antagonists. Expert Opin. Ther. Patents 2002; 12: 1403-1406.
71. Romero R, Sibai BM, Sanches-Ramos L, Valenzuela GJ, Veille J-C, Tabor B, Perry KG, Varner M, Murphy G, Lane R, Smith J, Shangold G, Creasy GW. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: A randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am. J. Obstet. Gynecol. 2000; 182: 1173-1183.
72. Valenzuela GJ, Sanches-Ramos L, Romero R, Silver HM, Koltun WD, Millar L, Hobbins J, Rayburn W, Shangold G, Wang J, Smith J, Creasy GW. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. Am. J. Obstet. Gynecol. 2000: 182: 1184-1190.
73. Tsatsaris V, Carbonne B, Cabrol D. Atosiban for preterm labour. Drugs 2004; 64: 375-382.
74. 1 receptor of rat, rhesus and human tissues. Life Sci. 1992; 50: 1953-1958.
75. Tahara A, Tsukada J, Tomura Y, Wada K-i, Kusayama T, Ishii N, Yatsu T, Uchida W, Tanaka A. Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells. Br. J. Pharmacol. 2000; 129: 131-139.
76. Barberis C, Morin D, Durroux T, Mouillac B, Guillon G, Seyer R, Hibert M, Tribollet E, Manning M. Molecular pharmacology of AVP and OT receptors and therapeutic potential. Drug News Perspect. 1999; 12: 279-292.
77. Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. J. Endocrinol. 1998; 156: 223-229.
78. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol. Rev. 2001; 81: 629-683.
79. 1a receptors in uterine contractions in rats; Implication for tocolytic therapy with oxytocin antagonists. Am. J. Obstet. Gynecol. 1996; 175: 1331-1335.
80. Yabe Y, Morita A, Miura C, Kobayashi S, Baba Y. Synthesis and biological activity of tetragastrin analogues modifying the tryptophan residue. Chem. Pharm. Bull. (Tokyo) 1977; 25: 2731-2734.
81. Yabe Y, Miura C, Baba Y, Sawano S. Synthesis and biological activity of somatostatin analogues modified at the tryptophan residue. Chem. Pharm. Bull. (Tokyo) 1978: 26: 993-997.
82. Nestor JJ Jr, Ho TL, Simpson RA, Horner BL, Jones GH, McRae GI, Vickery BH. Synthesis and biological activity of some very hydrophobic superagonist analogues of luteinizing hormone-releasing hormone. J. Med. Chem. 1982; 25: 795-801.
83. Prochazka Z, Slaninova J. The analogs of oxytocin and vasopressin with bulky amino acid in position 2. In Peptides 1994, Maia HLS (ed.). ESCOM: Leiden, 1995: 337-338.
84. Lammek B, Konieczna E, Kozlowski A, Szymkowiak J, Trzeciak HI, Kupryszewski G. The substitution of one amino acid residue in position 2 of the AVP molecule leads to a very potent antagonist. In Peptides 1994, Maia HLS (ed.). ESCOM: Leiden, 1995; 339-340.
85. 2 receptor antagonist design: a reassessment. In Peptides 1996, Ramage R, Epton R (eds). Mayflower Scientific: Kingswinford, 1998; 819-820.
86. 1b receptor. In Peptides for the New Millennium, Fields G, Tam J, Barany G (eds). Kluwer Academic Publishers: Dordrecht/Boston/London, 2000: 641-642.
87. Cheng LL, Stoev S, Manning M, Wo NC, Chan WY, Szeto HH, Durroux T, Mouillac B, Barberis C. Design of oxytocin antagonists which are strikingly more potent and selective in human receptor assays than atosiban. In Peptides Revolutions; Genomics, Proteomics and Therapeutics, Chorev M, Sawyer TK (eds). American Peptide Society, San Diego, CA, 2004; 725-726.
88. Maggi M, Fantoni G, Baldi E, Cioni A, Rossi S, Vannelli GB, Melin P, Akerlund M, Serio M. Antagonists for the human oxytocin receptor: an in vitro study. J. Reprod. Fertil. 1994; 101: 345-352.
89. Jasper JR, Harrell CM, O'Brien JA, Pettibone DJ. Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci. 1995; 57: 2253-2261.
90. Akerlund M, Bossmar T, Brouard R, Kostrzewska A, Laudanski T, Lamancewicz A, Serradeil-Le Gal C, Steinwall M. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. Br. J. Obstet. Gynaecol. 1999; 106: 1047-1053.
91. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 1963; 85: 2149-2154.
92. Merrifield RB. Solid phase synthesis. Science 1986; 232: 341-347.
93. Stewart JM, Young JD. Solid Phase Synthesis. Pierce Chemical Company: Rockford, IL 1984.
94. Manning M, Coy EJ, Sawyer WH, Acosta M. Solid-phase synthesis and some pharmacological properties of: 4-threonine analogs of vasopressins and vasotocin and of arginine-vasopressin and arginine-vasotocin. J. Med. Chem. 1973; 16: 463-466.
95. Manning M. Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin. J. Am. Chem. Soc. 1968; 90: 1348-1349.
96. Manning M, Coy E, Sawyer WH. Solid-phase synthesis of [4-threonine]-oxytocin. A more potent and specific oxytocic agent than oxytocin. Biochemistry 1970; 9: 3925-3930.
97. Konig W, Geiger R. A new method for synthesis of peptides: activation of the carboxyl group with dicyclohexylcarbodiimide using 1-hydroxybenzotriazole as additive. Chem. Ber. 1970; 103: 788-798.
98. Manning M, Przybylski J, Grzonka Z, Nawrocka E, Lammek B, Misicka A, Cheng LL, Chan WY, Wo NC, Sawyer WH. Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids. J. Med. Chem. 1992; 35: 3895-3904.
99. Bodanszsky M, du Vigneaud V. A method of synthesis of long peptide chains using a synthesis of oxytocin as an example. J. Am. Chem. Soc. 1959; 81: 5688-5691.
100. Bodanszsky M, Sheehan JT. Active ester and resins in peptide synthesis. Chem. Ind. 1964; 1423-1424.
101. Glass JD, du Vigneaud V. Solid-phase synthesis and pressor potency of [1-deamino-9-ethylenediamine]-lysine-vasopressin. J. Med. Chem. 1973; 16: 160-161.
102. Yajima H, Fuji N, Ogawa H, Kawatani H. Trifluoromethanesulfonic acid as a deprotecting reagent in peptide chemistry. J. Chem. Soc. Chem. Commun. 1974; 107-108.
103. Yajima H, Fujji N. Acidolytic deprotecting procedures in peptide synthesis. In The Peptides. Vol 5, Gross E, Meiehofer J (eds). Academic Press: New York, 1983; 65-109.
104. Hope DV, Murti VVS, du Vigneaud V. A highly potent analogue of oxytocin, desamino-oxytocin. J. Biol. Chem. 1962; 237: 1563-1566.
105. Rivier J, Kaiser R, Galyean R. Solid phase synthesis of somatostatin and glucagon-selective analogs in gram quantities. Biopolymers 1978; 17: 1927-1938.
106. Manning M, Wuu TC, Baxter JWM. The purification of synthetic oxytocin and analogues by gel filtration on Sephadex G-15. J. Chromatogr. 1968; 38: 396-398.
107. Holton P. A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br. J. Pharmacol. 1948; 3: 328-334.
108. Schild HO. pA, a new scale of the measurement of drug antagonism. Br. J. Pharmacol. Chemother. 1947; 2: 189-206.
109. Dyckes DF, Nestor JJ Jr, Ferger MF, du Vigneaud V. [1-β-mercapto-β,β-diethyl-propionic acid]-8-lysine-vasopressin, a potent inhibitor of 8-lysine-vasopressin and of oxytocin. J. Med. Chem. 1974; 17: 250-252.
110. Munsick PA. Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues. Endocrinology 1960; 66: 451-457.
111. Chan WY, Kelly N. A pharmacologic analysis on the significance of the chemical functional groups of oxytocin to its oxytocic activity and on the effect of magnesium on the in vitro and in vivo oxytocic activity of neurohypophysial hormones. J. Pharmacol. Exp. Ther. 1967; 156: 150-158.
112. Dekanski J. The quantitative assay of vasopressin. Br. J. Pharmacol. 1952; 7: 567-572.
113. Sawyer VM. Biologic assays for oxytocin and vasopressin. Methods Med. Res. 1961; 9: 210-219.
114. Phalipou S, Cotte N, Carnazzi E, Seyer R, Mahe E, Jard S, Barberis C, Mouillac B. Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J. Biol. Chem. 1997; 272: 26 536-26 544.
115. Kassis S, Henneberry RC, Fishman PH. Induction of catecholamine-responsive adenylate cyclase in HeLa cells by sodium butyrate. Evidence for a more efficient stimulatory regulatory component. J. Biol. Chem. 1984; 259: 4910-4916.
116. 1a receptors. Neuroendocrinology 1995; 62: 135-146.
117. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973; 22: 3099-3108.
118. Nilsson L, Reinheimer T, Steinwall M, Akerlund M. FE200 440: a selective oxytocin antagonist on the term-pregnant human uterus. Br. J. Obstet. Gynaecol. 2003; 110: 1025-1028.
119. Pierzyknski P, Lemancewicz A, Reinheimer T, Akerlund M, Laudanski T. Inhibitory effect of Barusiban and Atosiban on oxytocin-induced contractions of myometrium from preterm and term pregnant women. J. Soc. Gynecol. Investig. 2004; 11: 384-387.
120. Wisniewski K, Jiang G, Stalewski J, Galyean R, Alagarsamy S, Taki H, Schteingart CD, Riviere P, Croston G, Trojnar J, Nilsson A. Synthesis and in vivo activity of heptapeptide oxytocin antagonists. '3rd International and 28th European Peptide Symposium, September 5-10, 2004 Prague, Czech Republic'. J. Pept. Sci. 2004; 10: (Supplement): P564.
121. 8-deamino-vasotocin analogue. Br. J. Cancer 2003; 89: 930-936.
122. Gisin BF. The preparation on Merrifield-resins through total esterification with cesium salts. Helv. Chim. Acta 1973; 56: 1476-1482.